Trial Profile
A phase I, open-label, non-randomized, dose-finding, safety, tolerance and pharmacokinetic study of orally administered S-1 in combination with oxaliplatin and bevacizumab in patients with advanced tumors
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 26 Jan 2007
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- 26 Jan 2007 New trial record.